ALT5 Sigma (NASDAQ:ALTS) Trading Up 8.7% – Time to Buy?

ALT5 Sigma Corporation (NASDAQ:ALTS)’s stock price was up 8.7% on Friday . The company traded as high as $2.16 and last traded at $2.12. Approximately 4,296,207 shares changed hands during trading, an increase of 23% from the average daily volume of 3,500,505 shares. The stock had previously closed at $1.95.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ALTS shares. Wall Street Zen cut shares of ALT5 Sigma from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ALT5 Sigma in a research report on Thursday, October 30th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

ALT5 Sigma Stock Up 8.7%

The business’s 50 day simple moving average is $3.09 and its 200 day simple moving average is $5.97. The company has a debt-to-equity ratio of 1.45, a current ratio of 0.88 and a quick ratio of 0.88.

Insider Transactions at ALT5 Sigma

In other news, Director David C. Danziger bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 14th. The stock was acquired at an average cost of $7.30 per share, for a total transaction of $73,000.00. Following the purchase, the director owned 20,000 shares of the company’s stock, valued at approximately $146,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.65% of the company’s stock.

Institutional Trading of ALT5 Sigma

A number of hedge funds have recently made changes to their positions in the business. Profund Advisors LLC bought a new position in shares of ALT5 Sigma during the 3rd quarter worth approximately $28,000. First Citizens Bank & Trust Co. acquired a new stake in ALT5 Sigma during the 3rd quarter valued at $35,000. Savvy Advisors Inc. acquired a new stake in ALT5 Sigma during the 3rd quarter valued at $53,000. Arkadios Wealth Advisors bought a new position in ALT5 Sigma during the third quarter worth $62,000. Finally, Evernest Financial Advisors LLC acquired a new position in shares of ALT5 Sigma in the second quarter valued at $87,000. 6.27% of the stock is owned by institutional investors and hedge funds.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.